HUP0201284A2 - Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére - Google Patents

Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére

Info

Publication number
HUP0201284A2
HUP0201284A2 HU0201284A HUP0201284A HUP0201284A2 HU P0201284 A2 HUP0201284 A2 HU P0201284A2 HU 0201284 A HU0201284 A HU 0201284A HU P0201284 A HUP0201284 A HU P0201284A HU P0201284 A2 HUP0201284 A2 HU P0201284A2
Authority
HU
Hungary
Prior art keywords
active ingredient
quinazolindione
preventive
derivative
therapeutic drugs
Prior art date
Application number
HU0201284A
Other languages
English (en)
Inventor
Harukazu Fukami
Eiichi Kakizoe
Hideki Okunishi
Original Assignee
Suntory Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Limited filed Critical Suntory Limited
Publication of HUP0201284A2 publication Critical patent/HUP0201284A2/hu
Publication of HUP0201284A3 publication Critical patent/HUP0201284A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgya hatóanyagként kimázinhibítort tartalmazó gyógyszer,amely mellékhatásoktól mentes, és biztonságosan alkalmazható a bőrvagy egyéb belső szervek fibrózisának megelőzésére vagy kezelésére, ésamely gátolja a betegség kifejlődését, gátolja a szövődményekkifejlődését és javítja a beteg életminőségét. A hatóanyagkimázinhibítor egy (I) általános képletű vegyület, vagy annakgyógyászatilag elfogadható sója, ahol R1, R2, R3 és X küönböző alifásés aromás csoportokat jelent, A jelentése benzolgyűrű. Ó
HU0201284A 2000-02-22 2001-02-22 Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient HUP0201284A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000050502 2000-02-22
PCT/JP2001/001321 WO2001062292A1 (en) 2000-02-22 2001-02-22 Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient

Publications (2)

Publication Number Publication Date
HUP0201284A2 true HUP0201284A2 (hu) 2002-12-28
HUP0201284A3 HUP0201284A3 (en) 2003-02-28

Family

ID=18572274

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201284A HUP0201284A3 (en) 2000-02-22 2001-02-22 Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient

Country Status (8)

Country Link
US (1) US6500835B2 (hu)
EP (1) EP1192949A4 (hu)
KR (1) KR20010108519A (hu)
CN (1) CN1366461A (hu)
AU (1) AU3413401A (hu)
CA (1) CA2368366A1 (hu)
HU (1) HUP0201284A3 (hu)
WO (1) WO2001062292A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245978C (zh) 2000-02-22 2006-03-22 第一阿斯比奥制药株式会社 含有胃促胰酶抑制剂作为活性成分的预防和治疗各种与嗜酸性粒细胞增多有关的疾病的药物
AU3413601A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient
KR100902799B1 (ko) * 2001-08-24 2009-06-12 데이진 가부시키가이샤 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
WO2003055488A1 (en) * 2001-12-27 2003-07-10 Nippon Kayaku Kabushiki Kaisha Remedies or preventives for diseases in association with tissue fibrosis
JP2003335670A (ja) * 2002-03-15 2003-11-25 Toa Eiyo Ltd 癒着防止剤
AU2004266536A1 (en) * 2003-08-22 2005-03-03 Teijin Pharma Limited Drug containing chymase inhibitor as the active ingredient
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
AU2005310490B2 (en) 2004-12-02 2012-01-19 Daiichi Sankyo Company, Limited 7-membered ring compound, process for producing the same, and medicinal use thereof
JP5117382B2 (ja) 2006-05-31 2013-01-16 第一三共株式会社 ７員環化合物の製造方法
TWI532842B (zh) * 2009-06-11 2016-05-11 力博美科股份有限公司 針對凝乳酶之適體及其用途
WO2014124302A1 (en) 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists
US10842794B2 (en) 2014-02-07 2020-11-24 Támogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
US10124006B2 (en) 2014-02-07 2018-11-13 MTA Tämogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
WO2016134223A2 (en) 2015-02-19 2016-08-25 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
KR20170141757A (ko) 2015-04-30 2017-12-26 사이플루어 라이프 사이언시즈, 인크 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도
WO2017189828A1 (en) 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
EP3338780A1 (de) * 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
WO2019107532A1 (ja) 2017-11-30 2019-06-06 株式会社リボミック キマーゼに対するアプタマー及びその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5199279A (en) 1991-08-13 1993-04-06 Reynolds Martin M Drum contact freezer system and method
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
EP0581738A1 (de) 1992-07-30 1994-02-02 Ciba-Geigy Ag Herbizide Pyridylsulfonylharnstoffe
WO1996004248A1 (en) 1994-07-29 1996-02-15 Suntory Limited Imidazolidine derivative and use thereof
JPH08208654A (ja) 1994-11-24 1996-08-13 Wakamoto Pharmaceut Co Ltd キマーゼ活性を阻害し、かつ一酸化窒素生成を抑制する新規トリアジン誘導体
US5948785A (en) 1995-04-27 1999-09-07 The Green Cross Corporation Heterocyclic amide compounds and pharmaceutical use of the same
US5596111A (en) 1995-06-05 1997-01-21 North Dakota State University Method for preparation of carboxylic acids
JP3537231B2 (ja) 1995-07-24 2004-06-14 第一サントリーファーマ株式会社 ヒダントイン誘導体およびその用途
WO1997011941A1 (fr) 1995-09-28 1997-04-03 Suntory Limited Derives de la quinazoline et leurs emplois
JPH1087567A (ja) 1996-06-05 1998-04-07 Takeda Chem Ind Ltd フェノールエステル誘導体、その製造法及び用途
JPH107661A (ja) 1996-06-20 1998-01-13 Green Cross Corp:The 新規複素環式アミド化合物およびその医薬用途
AUPO062696A0 (en) 1996-06-24 1996-07-18 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
JPH1087493A (ja) 1996-09-18 1998-04-07 Shionogi & Co Ltd セフェム系化合物を含有するキマーゼ阻害剤
KR20000052775A (ko) 1996-10-25 2000-08-25 가마쿠라 아키오 신규한 헤테로사이클릭 아미드 화합물 및 의약으로서의 그의 용도
JPH10245384A (ja) 1997-03-05 1998-09-14 Teijin Ltd 新規トリアジンスルホン誘導体
JPH111479A (ja) 1997-06-11 1999-01-06 Nippon Steel Corp アミド結合を有するイソオキサゾール誘導体、並びにこれらを含有するキマーゼ阻害剤及びアンジオテンシンｉｉ産生抑制剤
EP1055683A4 (en) 1998-02-17 2007-07-25 Nippon Kayaku Kk NEW ACETAMIDE DERIVATIVE AND USE THEREOF
JPH11246437A (ja) 1998-03-05 1999-09-14 Yoshitomi Pharmaceut Ind Ltd 消化管粘膜保護剤
WO2000005204A1 (en) 1998-07-23 2000-02-03 Shionogi & Co., Ltd. MONOCYCLIC β-LACTAM COMPOUNDS AND CHYMASE INHIBITORS CONTAINING THE SAME
HUP0103387A3 (en) 1998-08-21 2002-07-29 Daiichi Asubio Pharma Co Ltd Quinazoline derivatives preparation thereof, medicament containing them and their intermediates
US6921766B1 (en) 1999-11-01 2005-07-26 Daiichi Suntory Pharma Co., Ltd. Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor
AU3413601A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient
CN1245978C (zh) 2000-02-22 2006-03-22 第一阿斯比奥制药株式会社 含有胃促胰酶抑制剂作为活性成分的预防和治疗各种与嗜酸性粒细胞增多有关的疾病的药物

Also Published As

Publication number Publication date
HUP0201284A3 (en) 2003-02-28
WO2001062292A1 (en) 2001-08-30
US6500835B2 (en) 2002-12-31
AU3413401A (en) 2001-09-03
EP1192949A1 (en) 2002-04-03
CA2368366A1 (en) 2001-08-30
EP1192949A4 (en) 2005-11-09
KR20010108519A (ko) 2001-12-07
CN1366461A (zh) 2002-08-28
US20020183338A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
HUP9802999A2 (hu) N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
FI943948A0 (fi) Heterosykliset hiilihappojohdannaiset
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
YU24503A (sh) Novi tiadiazoli i oksadiazoli i njihova upotreba kao inhibitora fosfodiesteraze-7
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
SE9901573D0 (sv) New compounds
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
EP1192949A4 (en) PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
HUP0201282A2 (hu) Hatóanyagként kinazolindionszármazék kimázinhibitort tartalmazó gyógyászati készítmények dermatitisz megelőzésére és kezelésére
SE0201837D0 (sv) Chemical compounds
SE9901572D0 (sv) New compounds
EP1695969A4 (en) ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE
IL112695A (en) Pharmaceutical compositions containing pyridazinone derivatives
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
MY122570A (en) Benzamide derivatives and drugs containing the same
SE9900190D0 (sv) New compounds
NO950177D0 (no) Farmakologisk aktive erivater
NO975790D0 (no) Anvendelse av allylaminderivater slik som terbinafin, i fremstillingen av et medikament for behandling av helikobacterpylori-infeksjonsassosierte sykdommer
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees